癌治療のためのトランスファーリン受容体を標的とするナノ粒子における多価性の複雑な役割
Jin Wang1, Shaomin Tian, Robby A Petros
1Departments of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA.
Journal of the American Chemical Society
|August 12, 2010
まとめ
転送リン受容体 (TfR) リガンドを用いた標的型ナノ粒子は,特定の腫瘍細胞の吸収を示しています. しかし,特定の細胞における予期せぬ毒性は,ナノデリバリー剤の設計における注意の必要性を強調しています.
科学分野:
- バイオテクノロジー バイオテクノロジー
- ナノメディシンは,ナノ医療です.
- がん研究 がん研究
背景:
- トランスフリン受容体 (TfR,CD71) は悪性組織で過剰発現し,重要な治療標的となっています.
- TfRリガンドと結合したナノ粒子は,標的の薬物投与の可能性を提供します.
研究 の 目的:
- TfRリガンドと結合したPRINT ((() ナノ粒子の標的投与と細胞毒性を評価する.
- 癌細胞におけるナノ粒子吸収と毒性の基礎となるメカニズムを調査する.
主な方法:
- トランスフリン受容体抗体 (NP-OKT9) またはヒトトランスフリン (NP-hTf) をPRINTナノ粒子に結合する.
- 様々なヒト腫瘍細胞系におけるTfR媒介の細胞吸収の評価.
- 細胞毒性およびアポトーシス経路活性化の評価 (caspase 3/7).
- 細胞内局所化と鉄補給の毒性への影響の調査.
主要な成果:
- NP-OKT9とNP-hTfは,腫瘍細胞におけるTfR媒介による特定の吸収を示した.
- ナノ粒子はラモスのB細胞リンパ腫に対して有意な毒性を示したが,固体腫瘍細胞系にはなかった.
- 毒性は,TfRリガンド密度とナノ粒子濃度と相関しています.
- NP-hTfとNP-OKT9の細胞毒性の異なるメカニズムは,鉄濃度の影響で示唆されました.
結論:
- TfRを標的とするナノ粒子は,特定の腫瘍細胞の吸収を達成しますが,予期せぬ毒性を示す可能性があります.
- リンガンド密度,多価性,および潜在的なオフターゲットの影響を注意深く考慮することは,ナノデリバリーエージェントの設計において極めて重要です.
- "有毒性の欠如"の主張は,特に標的分子を用いて徹底的な調査を必要とします.
関連する概念動画
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
The Early Endosome: Endocytosis of Transferrin
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.


